A new experimental pill, enlicitid, has been shown to reduce 'bad' cholesterol (LDL) by up to 60% in high-risk patients, according to a study published in the New England Journal of Medicine. Led by Ann Marie Navar at UT Southwestern Medical Center, the study involved nearly 3,000 participants and demonstrated significant improvements in cholesterol levels, although further research is needed to confirm its effectiveness in preventing heart attacks and strokes. Teljes cikk (Euronews.com)